- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
Experts discuss whether providers should wait for another complete scientific statement from the National Lipid Association (NLA) or new guidelines from organizations like the American Heart Association (AHA) before implementing the 2024 NLA recommendation for universal lipoprotein(a) (Lp[a]) measurement.
EP: 1.Lp(a) in ASCVD and Guideline Recommendations
EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening
EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing
EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
Video content above is prompted by the following:
The NLA’s 2024 recommendation comes as a “focused update” to its 2019 scientific statement on the use of Lp(a) in clinical practice. Should providers wait for another complete scientific statement from NLA—or for new guidelines from AHA or other organizations—before implementing this recommendation?
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
